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ABSTRACT 
With an increasing aging population, Alzheimer’s disease (AD) has become a social and 
economic problem to societies worldwide, affecting millions of people. However, 
pathophysiological events associated with AD are not well elucidated yet and current definitive 
diagnosis is only obtained after death through examination of brain tissue. In the last years, 
Metabolomics has been demonstrated to provide deep insights into the full complexity of the 
disease phenotype and has been established as a promising approach to provide disease-specific 
metabolite signatures. The incipient application of Metabolomics may potentially contribute in 
the elucidation of AD physiopathological processes and ideally may offer 
therapeutic/preventing mechanisms to slow or reverse AD progress. In this chapter non-targeted 
metabolomics approaches applied to AD investigation are described. 
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1. INTRODUCTION  
Alzheimer’s disease (AD) is the most prevalent form of late-life mental failure in humans [1,2]. 
It is expected that AD incidence will triple over the next 50 years [3]. AD pathology affects the 
central nervous system (CNS) leading a progressive destruction and atrophy of brain cortex 
especially those regions related to superior mental functions. Namely, neocortex and 
hippocampus areas are primarily affected in AD [4]. Clinically AD is characterized by the 
presence of intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau 
proteins [5] and Aβ peptide aggregates (Aβ) in form of extracellular amyloid plaques [6] and 
amyloid infiltrates in the brain microvasculature [7]. These formations are considered key 
factors in neuronal dysfunction and cell death [8-10]. Other neuropathological hallmarks for AD 
include synaptic loss and/or dysfunction, diminished neuronal metabolism and loss of multiple 
neurotransmitter systems [1]. These alterations in the CNS bring about an unspecific 
symptomatology that begins with cognitive deficits to remember autobiographical events 
specific to a time and place [11]. As the pathology advances to cortical brain areas the long-term 
memory becomes impaired and ordinary abilities including semantic memory and attention are 
affected leading to a dementia syndrome [12]. 
AD is preceded by a mild cognitive impairment (MCI) state followed by dementia, and it has 
been indicated that the annually conversion rate from MCI to dementia is about 15% [13] and 
reach up to 80% in a 6 years follow-up [14]. MCI is defined by a cognitive decline greater than 
expected for certain age and education level, but not severe enough to be considered dementia 
or to interfere notably with activities of daily life [13]. This condition is characterised by 
memory impairment that can be proved and diagnosed by objective measures [15]. Up to date, 
there is no clinical method to determine which patients with MCI will progress to dementia 
except for a long clinical follow-up [16]. The speed and severity of clinical progression after 
MCI diagnosis vary and depend on multiple factors, most not well elucidated yet. For instance, 
depression has been proposed as a risk factor for dementia and cognitive decline [17], 
postulated as causal effect by means of hippocampal damage [18] or as a possible prodromal 
state [19] of MCI state. There is a great clinical need to identify incipient AD in patients with 
MCI and many efforts are being made in the discovery of predictor markers of progression via 
the use of cognitive tests [20,21], structural and functional neuroimaging [12,22,23], CSF 
analysis [24,25], and other biomarkers, either isolated or in combination [26,27]. On the other 
hand, the USA National Institute of Aging and the Alzheimer’s disease Association is working 
on the determination of the best predictor factors in the progression from normal cognition 
(presymptomatic or preclinical state) to MCI [28]. Some of the proposed research criteria and 
markers for preclinical AD are summarized in Fig. 1 [28]. These initiatives are extremely 
important since there is evidence suggesting AD pathological processes begin years or even 
decades before dementia onset [29]. 
Leaving aside the detection and identification of the pre-dementia states, even the diagnosis of 
patients suffering an advanced AD needs to be improved. AD is routinely diagnosed following 
the criteria established in 1984 by the National Institute for Neurological and Communicative 
Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association 
(NINCDS/ADRDA, now known as Alzheimer’s disease Association) criteria [30]. These 
criteria establish that AD can exclusively be diagnosed with certainty at autopsy. A definitive 
AD diagnostic is only achieved with the detection of NFTs and Aβ in post-mortem brain tissue 
[31]. Nonetheless, CSF is considered a valuable source of AD biomarkers, very promising for 
the early detection and progress evaluation of AD [32]. Several markers, generally protein 
molecules, have been already linked to AD [33,34]. Until date, the ratio between total tau 
protein and Aβ peptide levels in CSF has been proposed as a high sensitive measure for 
diagnostic purposes for advanced AD patients, which in combination with brain imaging 
techniques is able to diagnose up to 90% of advanced AD patients, assuming a high economic 
burden per evaluated subject (ca. 6,000-10,000 euros approximately) [35]. NINCDS/ADRDA 
criteria includes standard comprehensive assessment protocol including clinical examination, 
brain imaging, electroencephalography, analyses of blood and CSF (including total tau, 
phospho-tau, and Aβ1-42) and a detailed neuropsychological evaluation to diagnose AD. If after 
these tests it is considered that the subject suffers mild-to-moderate AD, different therapeutic 
options are possible. Currently, there is no remedy for AD but symptomatic therapy. Most 
recommended medications for mild-to-moderate AD include cholinesterase inhibitors 
(donepezil, rivastigmine or galantamine) that increase the levels of acetylcholine in the brain. 
However controversy about the satisfactory results [36] or limited benefits [37] of these drugs 
has been reported [38]. A combination of cholinesterase inhibitors with memantine (N-methyl-
d-aspartate (NMDA) receptor antagonist) seems to produce consistent benefits in moderate-to-
severe AD [39,40] with respect to a single drug administration. The search for therapeutic 
treatments at all phases of cognitive decline is imperative since up to date, no drug can reverse 
pathological process of this chronic disease. On the other hand, there are evidences suggesting 
that concurrent pharmacologic and behavioral methods may exploit functional benefits for 
patients suffering from dementia [41,42]. Although no specific disease-modifying treatment has 
yet been shown to be effective for dementias, it is particularly important to develop effective, 
targeted treatments to halt or delay the onset of cognitive decline from preclinical and MCI 
states to AD related dementia. An accurate identification of AD cases at MCI state or, even 
better at preclinical state, might enable early therapeutic interventions to reduce considerably, 
stop or even reverse the numerous pathological, emotional and economic costs of the illness 
[43]. 
The distinction of preclinical AD stage from changes of normal ageing represents a major 
demand in AD investigation. Unlike MCI state, diagnostic criteria for this prodromal phase have 
not yet been established. In this sense, one of the main focuses of the scientific community is to 
elucidate the link between the neurodegenerative cascade of AD and the apparition of first 
clinical symptoms. At the same time, the lack of effective therapeutic treatment for AD entails 
an ethical conflict in the preclinical stage diagnosis because of the potential emotional 
repercussion. The discovery of biomarkers suitable to monitor the evolution and progression 
from the preclinical phases to MCI related to AD is particularly challenging and may offer key 
information to deepen in the origin, causes and pathophysiology of AD. The detection of AD 
biomarkers can be achieved via two different approaches: knowledge-based and unbiased. The 
traditional one consists of the “knowledge-based” or targeted (deductive method) approach and 
relies on a direct understanding of the neuropathological processes. Until date several studies 
have targeted protein biomarkers related to AD pathology, among which beta-amyloid peptide 
and its precursor (amyloid precursor protein, APP) stands out [44-46] followed by the analysis 
of other proteins such as tau [47,48] or BACE (β-site APP cleaving enzyme-1) [49,50]. From a 
genetic point of view, allelic variation of ApoE has been described as the most influential 
genetic risk factor to develop sporadic AD [51]. To a lesser extent, cholesterol [52,53] or 
homocysteine [54] have also been targeted as potential metabolic AD biomarkers. The great 
lack of knowledge of pathophysiological processes that govern AD makes the alternative 
“unbiased” approach more suitable than the targeted approach in the generation of new 
hypothesis [55] about the origin, causes and progression of AD. In contrast to targeted analysis 
of selected analytes, the goal of untargeted approach is to find biomarkers through the 
comprehensive study of the maximum number of molecules in a biological system. The use of 
omics technologies in biomarker discovery has evolved from traditional targeted to non-biased 
approaches. Omics technologies refer to a group of advanced analytical technologies used in a 
high-throughput manner to explore the composition, roles, and relationships of a variety of 
molecules in a biological system. Omics are able to significantly improve the experimental 
models that offer only a temporal snapshot of the huge complexity and dynamic nature of 
biological networks that govern human health and disease [56]. Thus, Transcriptomics [57], 
Proteomics [33,34] and Metabolomics [58-61] technologies have been applied in AD research 
and they are expected to significantly help in the advance of the investigation of biomarkers 
implicated in the pathogenesis of AD [62]. 
 
2. METABOLOMICS IN AD 
The development of new methodologies to discover early and high confident biomarkers related 
to AD progression is compulsory. This investigation will contribute to reveal mechanisms by 
which neurodegeneration starts and progresses, so far unknown [63]. Among omics 
technologies, Metabolomics intensifies variations occurring both in the proteome and the 
genome, and represents a faithful reflection of the organism phenotype in health and disease 
[59]. Metabolomics, the newest of the omics technologies, deals with the comprehensive study 
of the metabolome or the entire set of small molecules (about <1500 Da) in a biological system 
(cell, biofluid, tissue, or organism) at a time, under given conditions [64]. The metabolome 
corresponds to the end stage of all molecular events owing to gene variation and expression 
(genomics), protein expression and modification (proteomics), and environmental exposures in 
a biological sample [65]. Massive and high-throughput determination of metabolites in complex 
samples is a powerful tool to characterize organism phenotypes and to discover biomarkers for 
health/disease states [66]. Metabolomics is increasingly applied to AD investigation [67] due to 
the complex nature of the disease. In fact, increasing evidences suggest that AD is a 
heterogeneous and multifactorial disorder resulting from combination between the genetic 
susceptibility and environmental influences [68] including life-style factors [69]. Biological 
processes such as inflammation, cholesterol metabolism, oxidative stress and homocysteine 
homeostasis have been observed to be different in AD patients compared to control subjects in 
“knowledge-based” approaches, but these biomarkers did not achieved sufficient discriminatory 
power [70]. Since the causes of this neurological disease are still not clear, non-targeted 
Metabolomics opens new frontiers in AD investigation. The unbiased nature of these 
metabolomic strategies require especial attention on study design since metabolites have very 
different molecular structures (lipids, carbohydrates, nucleic acids, amino acids, organic acids 
and others) and are present in biofluids and tissues in a wide dynamic range of concentrations 
(pmol-mmol) [71]. Therefore the complete analysis of entire metabolome in biological systems 
is still challenging and no single analytical platform can cover the entire metabolic signature of 
a given biological sample. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) are 
by far the two analytical platforms most predominantly used in Metabolomics. NMR permits 
the analysis of complex mixtures of metabolites with little or no sample preparation in a rapid 
and non-destructive way [72] and has been largely applied in Metabolomics [73]. NMR was 
firstly used in AD Metabolomics in 1993 [74], 9 years before than the application of the first 
MS-based metabolomics study [75]. This analytical approach has been applied in AD 
investigation in a variety of applications as can be seen in Table 1. For instance NMR has been 
used to uncover AD metabolic biomarkers involved in specific metabolic pathways such as 
oxidative [76], lipid [77] and cholesterol [78] metabolism. 
Compared to NMR, MS technique is highly sensitive enabling broader surveys of the 
metabolome and provides spectral information for the identification process of metabolites [79]. 
The use of ultra-high resolution mass spectrometers (e.g., TOF, FT-ICR MS, Orbitrap®) is 
essential in MS-based metabolomics approaches, to obtain accurate mass measurements for the 
determination of elemental compositions of metabolites and for their tentative identification 
with the help of metabolite databases [80]. On the other hand, MSn experiments provide 
additional structural information for metabolite identification purposes, especially when product 
ions are analysed at high resolution (with Q-TOF, TOF-TOF, or LTQ-Orbitrap). Evaluation and 
comparison of NMR and MS analytical platforms on the application in Metabolomics have been 
extensively studied [79-82]. Both analytical platforms can be used as a standalone or in 
combination with previous separation techniques such as gas chromatography (GC), liquid 
chromatography (LC) or capillary electrophoresis (CE). The human metabolome include a great 
portion of polar compounds such as polyamines, amino acids or simple sugars. Compared to 
GC, both LC and CE can make possible the separation of higher polarity compounds and 
represent the two separation techniques most useful for medium to highly polar metabolic 
profiling. On the other hand, GC is especially suitable for the analysis of organic molecules and 
generally requires sample derivatization of metabolites to create volatile compounds. 
Two different and complementary analytical strategies are basically followed in non-targeted 
Metabolomics: metabolic “fingerprinting” and “profiling”. “Metabolic fingerprinting” has been 
proposed as a means of analyzing the total set of metabolites, avoiding biases against certain 
classes of compounds, for sample classification [83,84] and “metabolic profiling” is referred to 
identification and quantification of a predefined group of metabolites (chemically related 
metabolites or associated with a particular metabolic pathway) [64]. Metabolic fingerprinting is 
gaining extensive interest across a wide variety of disciplines with the emerging main focus on 
biomarker discovery for disease prognosis, diagnoses and therapy monitoring [85]. This 
approach offers a rapid biochemical snapshot of the metabolome [84] with the possibility of 
correlating the perturbations from the homeostatic or healthy state with disease. Moreover, 
metabolic fingerprints reveal characteristic metabolic patterns broadening our understanding of 
unknown pathological processes [86], which enhance its utility in AD biochemical alterations. 
In an ideal metabolic fingerprinting approach, metabolite extraction method and analytical 
platform should not be biased towards any group of molecules. In practice, these issues have not 
been resolved yet but tried to be minimized. The broad information obtained by metabolic 
fingerprinting approach make it the most attractive and suitable strategy for biomarker 
discovery [85], while at the same time, represents the most challenging and time-consuming 
approach in Metabolomics. In AD research, the obtaining of metabolic fingerprints is a recent 
practice by using both NMR [87-89] and MS-based [90-94] techniques. 
Metabolic profiling approaches are developed for the determination and quantitation of 
metabolites of a particular pathway or for a class of compounds. This strategy generates 
quantitative information of metabolites belonging to known biochemical pathways and 
physiological interactions [95]. Using metabolic profiling, optimized analytical design (sample 
treatment, analytical platform, etc.) for a group of compounds is performed optimizing 
sensitivity and specificity for the group of molecules of interest. The information obtained from 
the metabolic profiles not only describes the metabolic state of a certain sample but in many 
cases is used for comparison purposes. 
The combination of characteristics from both metabolic profiling (generally, a hypothesis-
driven approach) and metabolic fingerprinting (hypothesis-generating approach) represent a 
powerful and highly complementary methodology. In fact it can be especially useful to get the 
benefit from the potential to discover novel unforeseen metabolic factors or biomarkers in 
fingerprinting approaches with the option of demonstrating the observed changes of known 
metabolites or confirming the potential biomarkers by means of the metabolic profiling mode 
[96]. A recent study followed this comprehensive metabolomics approach in the investigation of 
biomarkers for AD by the comparison of postmortem brain tissue from AD patients and healthy 
control subjects [97]. First, a metabolic fingerprint to determine potential biomarkers and 
affected pathways in AD pathology was performed. Then the specific metabolic pathway related 
to potential AD biomarkers spermine and spermidine, namely biogenic polyamine metabolism, 
was explored in detail finding three more molecules altered due to AD pathology [97]. 
Although Metabolomics is still in its infancy in AD investigation, a number of studies have 
been published in the last years (Table 1), as this chapter will show. Most of them are based on 
the analysis of CSF, blood or post-mortem brain tissue samples, although in a lesser extent, 
urine has been also examined in the search of AD biomarkers [89,98]. 
 
2.1. Metabolomics and AD in CSF 
Metabolomics works focused on AD investigation are mostly based on the analysis of CSF. 
Main reason is that CSF composition is directly affected by the CNS. Therefore, alterations due 
to AD pathology will be more probably observed in this sample than in other biofluids. The role 
of CSF includes a mechanical protection of CNS against trauma, and transport of nutrients to 
ensure the homeostasis of CNS cells [99]. 
Prior to metabolomic analysis sample treatment is typically needed since CSF contains 
approximately 0.3 mg/mL protein [100] that may hinder metabolite analysis. Consequently, 
CSF sample treatment is essentially directed to protein removal by means of organic solvent 
addition [92,101] or by ultrafiltration [93,102,103]. The final metabolic extract composition will 
depend in a great extent on the sample treatment [104] and it will be selected mostly regarding 
the metabolomic approach and the analytical technique that will be afterwards applied. 
In some metabolic applications an additional step of purification is needed. For instance, Myint 
et al., [105] removed CSF protein content using 5 kDa centrifuge filters and then an additional 
step of solid phase extraction (SPE) through a polymeric sorbent was carried out to purify 
hydrophilic metabolites. In that study, analysis of CSF samples from AD diagnosed subjects 
(n=18) and healthy controls (n=18) was carried out by the development of a new 
chromatographic method based on nanoLC-Q/TOF in the positive ionization mode. By using 
multivariate analysis satisfactory separation was obtained among two groups of subjects using 
PCA statistics [105]. In that study, an extensive optimization of stationary phases for separation 
of weak and strong cationic metabolites was required. 
When we speak about the type of metabolic species covered by a certain technique, it is also 
worth mentioning that the analysis of polar metabolites is specially challenging in 
Metabolomics. CE is a fast and high-resolution separation technique especially suitable for the 
separation of ionic and highly polar molecules that cannot be easily obtained by LC [104] and 
has been applied in the investigation of early biomarkers related to AD progression, from MCI 
and healthy states [93,102]. According to a previous statement that considered free amino acids 
as important molecules in neurotransmission, receptor function and implicated in neurotoxicity 
[106] Samakashvili et al. determined chiral amino acid alterations in progression to AD. For 
that purpose a micellar electrokinetic chromatography (MEKC) with β-cyclodextrin as a chiral 
selector and laser induced fluorescence (LIF) detection, was developed. This enantioselective 
method permitted the determination of 11 amino acids in CSF samples from healthy subjects, 
MCI patients who progressed to AD in a two years follow-up period, MCI patients without 
progression to AD in that follow-up period, and AD patients. Decreased levels of L-Arginine, 
L-Glutamic acid, L-Aspartic acid and L-Lysine, and increased levels of gamma-amino butyric 
acid were related to the progression of MCI patients to AD [102] and were suggested as 
potential early biomarkers. The concept of early diagnostic biomarkers has a long history, with 
many studies showing that AD biomarkers can be used to predict conversion from MCI to AD. 
As stated in introduction section still now the clinical diagnosis of AD requires the presence of 
MCI state [107] and up to date, there is no clinical method to determine which MCI cases will 
progress to AD except for a long clinical follow-up period [43]. The discovery of markers that 
indicate progression from MCI to AD is still an unresolved issue, and a topic of high relevance 
in AD research. Several groups have been addressed this issue using metabolomic approaches in 
CSF samples. Thus, CSF metabolic fingerprints from patients showing different cognitive status 
related to AD were obtained by CE-MS [93]. In that study 85 CSF samples were obtained from 
individuals in four different cognitive states, namely age-matched controls, patients who at the 
sample collection time suffered from MCI, and finally a group of AD patients. After a clinical 
follow-up period of two years, some patients with MCI developed AD and others remained 
stable. After CE-MS analysis and extensive data processing (peak detection, filtering, migration 
time alignment, normalization, etc.) 71 metabolites were detected in the 85 samples. As a result 
of the multivariate statistical analysis, a 90% of correct sample assignment was achieved with 
the determination of 10 potential metabolic biomarkers [93]. The most similar metabolic 
fingerprints were observed when MCI patients without development to AD and control subjects 
were compared. That finding led to the merger of these two groups of samples as one “non-AD” 
sample group and other discriminant analysis was performed reaching up to 97% of correct 
assignment with the determination of 14 potential metabolic markers. Increased levels of 
choline and a decreased concentration of carnitine and creatine were observed in MCI patients 
who progressed to AD compared to the other groups of samples under study [93]. UHPLC-MS 
analytical platform was used to improve metabolome coverage of CSF samples [103]. Thus, by 
using RP/UHPLC-MS and HILIC/UHPLC-MS, and a subsequent data processing, a total of 524 
high-confident metabolites were detected in CSF samples. After a discriminant analysis, a 
98.7% correct assignment was achieved with the determination of 17 significantly different 
metabolites among the four groups of samples (control, MCI with progression to AD, MCI 
without progression to AD and AD). Furthermore values above 95% for sensitivity and 
specificity were obtained. In MCI patients who progressed to AD, decreased levels of a 
neuroprotective metabolite as taurine and increased levels of neurotoxic metabolites such as 
dopamine-quinone or methylsalsolinol were observed [103]. A less common analytical 
approach in Metabolomics, HPLC with electrochemical array detection (ECA), has been applied 
to study metabolic signatures from 114 CSF samples from three groups of patiets: 40 control 
individuals (healthy), 36 subjects with MCI and 38 AD patients [108]. ECA is an extremely 
selective and sensitive detection technique with simpler and cheaper instrumentation, but 
compared to NMR or MS, less structural information is obtained by LC-ECA. Before analysis, 
CSF proteins were precipitated by methanol addition and metabolic fraction was then analyzed 
by LC-ECA. As a result 21 of a total of 71 detected metabolites could be identified by the 
analysis of reference standard mixtures. Patients presenting AD and MCI showed elevated 
levels of methionine, whereas the methionine/reduced glutathione ratio was decreased, 
suggesting a glutathione depletion associated with AD pathology [108]. In that work a 
correlation between metabolite levels and concentration of Aβ1-42, total tau and phospho-tau 
proteins in CSF was carried out. As a result, an association between the levels of 
vanillylmandelic acid and xanthine with total-tau protein in CSF was found, inferring that 
norepinephrine pathway and purine pathway may be involved in total tau aggregation and 
pathology generation [108]. Later, the same research group in collaboration with other 
laboratories combined the metabolic information obtained by HPLC-ECA with that obtained 
from GC-TOF MS platform [109]. In that work 40 AD patients and 38 healthy control subjects 
were considered. After the GC-TOF MS analysis and statistical evaluation, higher levels of two 
metabolites showed the most consistent association with the disease. However authors declared 
that unknown identity of these two metabolites hinders biological interpretation [109]. 
Other study that deepened in the disease phenotype by means of the comparison of AD and 
healthy subjects was published by Czech et al., in 2012 [92]. CSF samples from 79 AD patients 
and 51 age-matched controls were studied. CSF deproteinization and metabolite fractionation 
(polar and no polar metabolites) was accomplished by using a mixture of ethanol and 
dichloromethane. Polar and no polar metabolic fractions were analyzed by GC-MS and LC-
MS/MS, respectively. More than 340 metabolites were determined. After statistical analysis an 
interesting finding was highlighted: by using univariate statistical analysis female AD patients 
showed more significant changes than male AD patients, compared to control subjects. 
Cysteine, uridine, cortisol, 3-methoxy-4-hydroxy phenylglycol, dopamine, noradrenaline and 
normetanephrine were significantly different in AD patients compared to control group. Then, 
discriminant analysis showed cysteine and uridine as the best metabolite pair to predict AD with 
sensitivity and specificity values of 75% (Fig. 2) [92]). 
The assessment of metabolic changes related to the beginning and progress of AD could 
improve the diagnosis and monitoring of AD but, in a more challenging scope, metabolic 
patterns could even help to evaluate the risk of healthy people to develop the disease in the 
future or the detection of subjects in the prodromal state of the disease. As stated in the 
introduction section, the investigation of early biomarkers of the long preclinical stage of AD 
could improve our understanding on AD pathophysiology including the development of new 
therapeutic targets to revert AD pathology. Focused on this idea, Jukarainen et al. analyzed CSF 
samples from 44 neurological controls who did not present any sign of dementia or chronic 
neurological diseases [90]. Subjects were divided into two groups consisting of 10 individuals 
who presented a typical concentration of AD protein markers, namely reduced soluble Aβ1-42 
and increased tau concentrations in CSF, and 34 control subjects with normal levels of AD 
protein markers in CSF. After NMR analysis of the samples, a curve fitting method based on 
constrained total line shape method showed that 31 metabolites covered the 85% of the total 
spectral intensity. However, only one metabolite was significantly different between the two 
groups of subjects, namely creatinine was higher in CSF from subjects with typical AD markers 
concentrations [90]. 
One of the biochemical processes that have covered much of the research performed on AD 
over the last years is the oxidative stress mechanisms [110]. Mitochondrial dysfunction has been 
suggested to underlie AD pathophysiology [111]. Deposition of heavy metals and alteration of 
the mitochondrial functionality are some of the facts and effects of oxidative stress observed in 
AD process [112]. Given its importance, a number of reviews have tackled this complex topic 
[112-115]. To explore this aspect at metabolomics level, oxidative stress related metabolites 
were studied using a profiling approach [76]. Thus, CSF samples from 48 individuals (12 AD 
patients, 19 with multiple sclerosis and 17 control subjects) were analyzed by 1H NMR. After 
collection CSF samples were lyophilized and no protein removal was required. In agreement 
with brain oxidative metabolism impairment, increased concentrations of several amino acids 
(alanine, lysine, valine, leucine or isoleucine, tyrosine and glutamine), acidic molecules (lactate 
and pyruvate) and inositol were found in AD samples [76]. 
 
2.2. Metabolomics and AD in plasma and serum 
Lumbar puncture to obtain CSF can produce several side effects [116]. Headache lasting less 
than one week occurs in up to 40% of patients representing the most common complication after 
lumbar puncture. Occasionally it is accompanied by nausea, vomiting, vertigo, reduced hearing 
and blurred vision. Other complications, including headaches lasting from 8 days to 1 year, 
cranial neuropathies, continued backache, nerve root injury, and meningitis, are rare, following 
less than 1% of lumbar punctures [117]. In addition to these side effects, lumbar puncture is a 
complicated [118] and expensive procedure so other alternatives such as peripheral blood could 
be of interest in the search of biomarkers related to AD. 
From the clinical point of view, there is a clear trend toward the analysis of minimum invasive 
samples (eg. blood or urine) for biomarkers search [119]. CSF is constantly exchanged and 
cleared via the blood [120]. This direct contact between CSF and blood encourages 
investigating this biofluid (plasma, serum and/or cells) which could reflect pathological changes 
in the brain [121]. However, exchanges between blood and CSF are not well elucidated yet and 
thus blood biomarkers usefulness is limited owing to the highly selective blood-brain barrier 
[70]. Since 2000s important efforts to find reliable AD biomarkers in peripheral blood following 
proteomic approaches have been carried out with moderate success [122]. In this sense, 
Metabolomics can be considered a relatively little explored technology, which may offer 
valuable information. Recently, Trushina et al. [123] established to what extent metabolic 
changes observed in CSF were or not reflected in plasma obtained from the same individuals. 
Metabolic fingerprints from CSF and plasma from AD (n=15), MCI (n=15) and control (n=15) 
individuals was compared to find the correlation between both biofluids and also to uncover 
biomarkers of AD progression. Integrated information from CSF and plasma samples was used 
to select and validate reliable plasma biomarkers related to AD [123]. As expected, the number 
of affected pathways in both biofluids increased with disease progression. Interestingly 
compared to control subjects near 30% and 60% of the metabolic pathways altered in the CSF 
of MCI and AD patients respectively, were also affected in plasma samples from the same 
individuals showing certain correlation between biofluids [123]. Amino acid and dipeptide 
content correlation between CSF and plasma was also accomplished by Fonteh et al. including 
also urine in that case [98]. CSF, plasma and urine from 8 AD patients and 8 control subjects 
were submitted to metabolite extraction. Briefly the extraction of the compounds of interest of 
200 µL of CSF, 100 µL of plasma and 200µL of urine was performed by a solid phase 
extraction and followed by derivatization. Amino acids and dipeptides were then detected by 
LC-MS/MS and differences between AD and control groups were determined in the three 
biofluids. As a result 23, 37 and 28 metabolites could be detected in CSF, plasma and urine 
respectively, and were compared between control and AD subjects. As can be seen in Fig. 3 
[98] metabolic variations due to AD were very different among the three biofluids. Altered 
metabolites due to AD pathology were identified and related to different biochemical processes 
such as neurotransmission (L-Dopa and dopamine), urea cycle/detoxification or NO formation 
(arginine, citrulline, ornithine), inhibitory processes (glycine) and antioxidation (carnosine) 
[98]. 
With the aim to detect potential metabolite biomarkers of AD in plasma, Li et al. [91] compared 
the metabolic fingerprints obtained by UHPLC-MS, from 20 control subjects and 20 AD 
patients. The statistical analysis by means of a PCA showed metabolic changes between AD and 
control samples mainly associated with nine potential biomarkers. Tryptophan, different 
lysophosphatidylcholines and sphingosines were highlighted as the metabolites that most 
differentiated AD from control groups of plasma samples [91]. In a different work, in order to 
monitor the progression markers to AD, plasma samples from control, MCI without progression 
to AD (in a 1-4-year follow-up), MCI who progressed to AD (in that follow-up period) and AD 
diagnosed subjects was carried out [124]. In that work, two different analytical platforms were 
used to widen the metabolome coverage. GCxGC-MS method was developed for the analysis of 
amino acids, free fatty acids, ketoacids, organic acids, sterols and sugars, while UHPLC-MS 
was optimized for the determination of lipids [124]. As a result, 683 metabolites (139 lipids and 
544 polar compounds) were determined. The high degree of co-regulation among the detected 
molecules was represented by clustering metabolites into subsets following the Bayesian model. 
7 and 6 clusters were obtained for UHPLC- and GCxGC-based metabolomics data, respectively. 
An alteration of pentose phosphate pathway between the two groups of MCI patients (MCI with 
and without progression to AD) together with an overall trend towards lower lipid levels in AD 
patients was observed [124]. Those samples with lower lipid contents were associated to 
processes linked to membrane lipid remodeling in AD patients. Lipids are not only major 
constituents of cell membrane physiology but are involved in crucial processes constituting one 
of the main focuses on Metabolomics. The vast majority of AD metabolic profiling studies of 
peripheral blood samples are focused on the investigation of lipid-related metabolites. 
Alteration in AD lipid metabolism has been suggested since brain tissue from AD patients 
display a higher occurrence of “adipose inclusions” or “lipoid granules”, already observed by 
Alois Alzheimer when he first described the disease [125]. In fact, a close link between lipid 
metabolism and AD has been established when the ɛ4 allele of the apolipoprotein E (ApoE) 
gene was identified as the strongest genetic risk factor for AD [126,127]. ApoE encodes a ~34 
kDa protein that serves as a crucial regulator of cholesterol metabolism in the brain and of 
triglyceride metabolism throughout the body. The processes by which ApoE mediates the 
uptake of lipoprotein particles in the brain via the low-density lipoprotein (LDL) receptor 
related protein and the very low-density family lipoprotein receptor have been already reviewed 
and described in detail [128,129]. Several evidences suggest that systemic lipid levels associate 
more strongly with the development of AD than previously assumed [130] and may vary in the 
progression to AD. To determine the molecular insights on the potential early lipid biomarkers, 
serum samples from 19 MCI and 26 control subjects were studied [77]. To obtain information 
on three different groups of metabolites, namely lipoproteins, polar metabolites and lipids, three 
NMR approaches were optimized. Lipoproteins group was analyzed after the application of 
optimized NMR conditions to detect macromolecules (mainly lipoprotein lipids and albumin). 
To obtain information about polar metabolites macromolecules signals were suppressed by the 
application of a pulse sequence. Finally lipid signals were detected after the breakdown of 
lipoprotein particles. Information obtained from the three groups of metabolites was afterwards 
combined and correlated with clinical data reported from the individuals under study. 
Interestingly, vascular factors, metabolic syndrome and cognitive decline were shown to be 
closely interrelated. Furthermore lower omega-3 fatty acids, sphingomyelin and 
phosphatidylcholine appear to be associated with AD risk factors presence, in MCI patients 
[77]. 
Bile acids have also been highlighted as possible metabolic markers of AD progression through 
a metabolic fingerprinting approach [131]. Plasma samples from 10 control subjects, 12 MCI 
and 16 AD patients were analyzed by UHPLC-MS/MS. After the PCA did not show any 
grouping of subjects by disease state, a partial least-squares discriminant analysis (PLS-DA) 
was applied showing separation for the three groups of samples. Increased levels of 
glycocholate, glycochenodeoxycholate and glycodeoxycholate were observed in MCI and AD 
patients. However, the unsuitability in the validation of the PLS-DA model for disease 
prediction and diagnosis was attributed by the authors to the high levels of inter- and intra-
subject variability and the small number of samples. The same problem was considered in 
another study by Sato et al. [132] where plasma from 10 control subjects, 10 MCI and 10 AD 
patients were analyzed by LC-MS. Lysophopholipid (18:1) was revealed as potential early 
biomarker because was observed gradually decreased in the progression to AD [132]. 
Novel approaches such as the non-targeted multi-dimensional mass spectrometry-based shotgun 
lipidomics (MDMS-SL) has also been applied to study AD. By using MDMS-SL approach, 
plasma from 26 AD patients and 26 cognitively normal subjects by ESI-QqQ MS were analyzed 
in the negative ion mode [133]. More than 800 lipid related molecular species from 9 classes of 
lipids (choline glycerophospholipid, lysophosphatidylcholine, ethanolamine 
glycerophospholipid, phosphatidylinositol, sphingomyelin, ceramide, triacylglycerol, 
cholesterol and cholesterol esters) were detected in plasma samples. Significant reductions of 
sphingomyelin and significant increase in ceramide content were observed in AD patients 
suggesting that the increased ceramide content might result from the accelerated 
sphingomyelins hydrolysis or increased biosynthesis in brain [133]. 
A number of epidemiological studies have shown a potential link between cholesterol lowering 
compounds, especially statins and a strongly decreased prevalence or incidence for dementia 
[134-136]. These evidences may indicate that targeting lipid metabolism [137] and more 
specifically cholesterol related metabolites in humans may be a potential strategy for AD 
prevention. Most predominant pathways related to clearance of key protein AD markers which 
are affected by cholesterol are described elsewhere [137]. For instance it was observed higher 
plasma cholesterol levels in individuals with the ε4 allele of ApoE, which elevates the risk for 
early (< 65 years of age) AD onset [138]. In agreement with these findings, cholesterol has been 
highlighted in a recent study as a powerful biomarker for AD [139]. After a preliminary 
discovery and identification of demosterol and cholesterol as potential AD biomarkers, a LC-
MS method was optimized to quantify these two metabolites [139]. The analysis revealed that 
desmosterol was found to be decreased in AD vs. controls plasma. The developed analytical 
method to quantify desmosterol and cholesterol revealed that desmosterol and the 
desmosterol/cholesterol ratio were significantly decreased in AD patients. Results were 
confirmed with a validation group of 109 plasma samples from clinically well described 
patients. 
 
2.3. Metabolomics and AD in post-mortem brain tissue 
Post-mortem brain tissue (BT) has brought about the main theories to explain origin and to 
design treatments for AD [140]. In contrast to plasma or CSF biofluids, the brain area or region 
of tissue must be carefully selected in the study design since metabolite composition is not 
homogeneous. Commonly affected regions in the brain include the association of cortical and 
limbic areas with especial damage of the cerebral cortex, certain subcortical regions and the 
hippocampus. Although amyloid plaques and NFTs are differentially distributed among AD 
patients, autopsies have shown predominance towards the temporal lobe. Contraction of 
cerebral cortex and hippocampus and increase of brain ventricles are other alterations observed 
in post-mortem brain tissue of AD patients. This complexity makes the majority of 
metabolomics studies to analyze several brain regions. For instance, post-mortem BT samples 
from frontal, parietal and occipital lobe from 10 control health subjects and 10 AD patients have 
been studied by using a metabolomic approach [97]. Metabolite extraction was performed on 
frozen grinded samples by the addition of methanol and Tris-HCl as solvent and followed by 
ultrafiltration to discard macromolecules. Metabolic fingerprinting by UHPLC-TOF MS 
analysis was primarily used to evaluate the diversity of low-molecular-weight molecules 
patterns from the frontal, parietal and occipital lobes in the positive and negative ion modes. 
After a multivariate statistical analysis, a total of 431 metabolite species were selected to 
identify possible biomarker candidates based on all brain regions under study. Five possible 
biomarkers in the frontal and parietal lobe areas were observed. Among them, identity of 
spermine and spermidine was confirmed by comparison with chromatograms and MS spectra of 
commercial standards. With the aim to increase the sensitivity and selectivity toward polyamine 
analysis, a derivatization procedure was applied to all the brain tissue samples by using of 4-
(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (DBD-F). Then the analysis was 
performed by UHPLC-MS/MS [97]. As a result, other polyamines were uncovered linked to AD 
pathology: an increase of putrescine, acetylspermidine and acetylspermine in AD frontal lobes 
was observed. In that work, Authors suggested a new theory shown in Fig. 4 [97] based on the 
increase in the activity of ornithine-decarboxylase enzyme induced by the amyloid plaques 
and/or neurofibrillary tangles and the effects of polyamines on N-methyl-D-aspartate (NMDA) 
receptors in the AD brain. In a different work, UHPLC-MS was also the selected analytical 
platform [94] to study neocortex metabolic fingerprints from post-mortem BT of 15 AD patients 
and 15 control healthy subjects. After an orthogonal projection to latent structures-discriminant 
analysis (OPLS-DA) (Fig. 5) and a t-test, 34 and 32 candidate biomarkers were observed to be 
statistically different in the two groups of samples, in the positive and negative ion modes, 
respectively [94]. 
Polar biomarkers have also been investigated by NMR [88] in post-mortem BT samples. These 
samples were treated with perchloric acid and metabolic extracts were analyzed to compare AD 
with amyotrophic lateral sclerosis (ALS) [88]. After multivariate statistical analysis of the 8 AD 
and the 11 ALS samples, a high score in the statistical parameters of OPLS was obtained with 
the exclusion of one AD sample. Increased concentration of branched amino acids, alanine, 
acetate, glutamine, glutamate and glycerophosphocholine in AD patients was observed when 
compared to ALS [88]. 
One of the possibilities to overcome the difficulty to obtain BT samples is the use of animal 
models reproducing certain characteristics of the AD pathology. In this sense, numerous 
transgenic mouse models have been used in AD investigation. Most common mice used in AD 
investigation, express human mutant amyloid precursor protein (APP). There are APP mutants 
mice that develop robust amyloid plaque pathology (e.g. Tg2576 (K670N, M671L) and 
TgCRND8(KM670/671NL + V717F)), presenilin protein mutants (e.g. M146L) and biogenic 
transgenic mice that express not only mutant APP but also mutant presenilin protein (PS) (e.g. 
APP/PS1)[141-145]. Using APP mutants, metabolic fingerprints of eight different brain regions 
of TgCRND8 mice (5 young and 3 aged mice) and control mice (4 young and 5 aged mice) 
were obtained by NMR [87]. Decreased levels of N-acetyl-l-aspartate, glutamate, glutamine, 
taurine (exception hippocampus), γ-amino butyric acid, choline and phosphocholine, creatine, 
phosphocreatine and succinate were observed in hippocampus, cortex, frontal cortex (exception 
γ-amino butyric acid) and midbrain of transgenic animals. Moreover, an increase in lactate, 
aspartate, glycine (except in midbrain) and other amino acids including alanine (exception 
frontal cortex), leucine, isoleucine, valine and water soluble free fatty acids were observed in 
the TgCRND8 mice. Furthermore, the combination of histological and metabolic data 
demonstrated that the hippocampus and cortical regions were affected in the mutant mice with 
an increase severity as the mice aged. In addition midbrain and cerebellum were found to be 
partly affected in mutant mice [87]. 
Trushina et al. studied the mitochondrial dynamics and function (motility, distribution, 
ultrastructure, etc) in neurons and brain tissue of three transgenic mice models expressing 
mutant human APP (Tg2576), PS1 (M146L mice) and the double mutation APP/PS1 [111]. 
Once mitochondrial trafficking, distribution, morphology and function were demonstrated to be 
affected in brain tissue from all three transgenic mice prior to the onset of cognitive decline, a 
metabolic profiling of brain tissue was carried out. GC-MS combined with multivariate 
statistical analysis by means of PLS-DA showed different gender related metabolic profiles 
leading to the comparison exclusively of females of all types of mice (three transgenic and one 
control mice). As a result, significant alterations in the levels of metabolites involved in energy 
metabolism including nucleotide metabolism, mitochondrial Krebs cycle, energy transfer, 
carbohydrate, neurotransmitter and amino acid metabolic pathways, were observed to be linked 
to familial AD [111] (Fig. 6). 
As stated in the previous section, a tight link between AD and lipid metabolism has been 
already described. Namely, high dietary cholesterol has been suggested to accelerate 
pathologies related to Aβ deposition [146] and furthermore, cellular cholesterol facilitates Aβ 
generation in vitro and in vivo [147,148]. In a recent study, Wisniewski et al. [78] focused on 
the investigation of cholesterol metabolism in 19 post-mortem human BT (9 AD patients and 10 
control subjects). Due to the low polarity of the metabolites involved in cholesterol pathways, a 
chloroform based solvent was used to extract the metabolites from BT samples. After sample 
analysis by HPLC-MS and confirmation by NMR, the proportion of desmosterol (a precursor of 
cholesterol) was found to be decreased in AD patients compared to age-matched controls. In 
another study, different metabolites related to lipid metabolism were observed to be altered in 
the progression to AD [75]. Samples under study included different post-mortem brain regions 
from 22 subjects, who at the time of death, had a clinical dementia rating score (from Morris 
[149]) of 0 (no dementia, n=5), 0.5 (very mild dementia, n=3), 1 (mild dementia, n=4), 2 
(moderate dementia, n=6), or 3 (severe dementia, n=4). Lipid extracts were analyzed by a direct 
infusion ESI/MS in the negative ion mode. Sulfatides, a class of sulfated galactocerebrosides, 
decreased up to 58 % in white matter and were found to be depleted up to 93% in gray matter at 
the earliest clinical stage of AD (0.5 dementia score). Authors surmised sulfatide deficiency as 
the earliest clinical stage of AD suggesting that its deficiency in AD may begin prior to the 
appearance of clinical symptoms [75]. 
 
3. CONCLUSIONS AND FUTURE RESEARCH 
In this chapter, metabolomics approaches applied to AD investigation have been presented. It 
can be observed that Metabolomics has become an important tool in the discovery of new 
diagnostic and prognostic AD biomarkers in different samples. Up to date, human CSF has been 
the preferred biofluid for the investigation of AD metabolic biomarkers as it can closely reflect 
brain specific changes. However, there is a clear trend toward the use of less invasive sample 
analysis. Research on the metabolites exchange through the blood brain barrier and correlation 
in metabolic concentration between CSF and blood represent a challenge for future 
metabolomics studies. 
To date, the frame in the discovery phase, within the global biomarker finding process, is the 
common aspect of all metabolomics works linked to AD. Thus most of metabolomics studies 
have been focused in the search of new biomarker candidates in the apparition and development 
of AD with high impact on novel hypotheses generation. Currently, to move forward, there is a 
growing need to reliable validate those findings increasing the cohort of clinical patients, to 
measure and validate the potential of the revealed biomarkers.  
Of particular importance in AD investigation is the discovery of biomarkers expressed before 
clinical symptoms appear. Pre-symptomatic events research represents an approach of special 
relevance in AD research for the potential impact on early therapy and disease progression 
understanding. Metabolomics works shown in this chapter have proven how the comparison of 
different metabolic fingerprints and metabolic profiles procurement from different phenotypes 
(health, MCI, AD) can be used to detect specific metabolic changes, potential biomarkers and 
altered metabolic pathways leading to the understanding of disease progression. Deepening in 
the mechanisms of disease will provide a source of potential new biomarkers helpful for early 
diagnosis, prognosis, prediction of response to therapy and disease progression.  
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FIGURES 
Figure 1. Graphic representation of the proposed staging framework for preclinical AD. Note that 
some individuals will not progress beyond Stage 1 or Stage 2. Individuals in Stage 3 are postulated 
to be more likely to progress to MCI and AD dementia. Abbreviations: AD, Alzheimer's disease; 
Aβ, amyloid beta; PET, position emission tomography; CSF, cerebrospinal fluid; FDG, 
fluorodeoxyglucose, fMRI, functional magnetic resonance imaging, sMRI, structural magnetic 
resonance imaging. (Reproduced from [28]). 
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Figure 2. Determination of analytes contributing significantly to separation between AD patients 
and healthy controls by O-PLSDA of the CSF data set. (A) OPLS-DA score plot for light AD 
patients (MMSE.22) vs. controls. (B) OPLS-DA coefficient plot for light AD patients (MMSE.22) 
vs. controls. Cysteine and uridine are the most relevant analytes for separating light AD patients 
(MMSE.22) from healthy subjects. (Reproduced from [92]). 
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Figure 3. Changes in free amino acid (FAA) and dipeptide (DP) concentrations in AD samples. 
After LC/MS2 analysis, mole quantities (nmol=dl) of FAAs and DPs in samples from subjects 
without or with AD were calculated. Then the change in the mean concentration of FAA and DPs in 
AD (n=8) compared to healthy controls (n=8) was achieved and expressed as the % change in AD 
compared to controls (*p<0.05). (Modified from [98]). 
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Figure 4. Metabolic pathway of polyamines. Increased levels of spermidine, spermine, putrescine, 
acetylspermidine and acetylspermine without a change of ornithine in AD pathology were observed. 
One theory suggests that the NMDA receptor excitotoxicity is caused by an excess of spermidine 
and spermine due to ornithine decarboxylase activity induced by plaque and/or tangle deposition in 
specific brain regions. (Reproduced from [97]). 
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Figure 5. (A) UHPLC ESI+ chromatogram of the polar extract of post-mortem brain tissue. (B) The 
scores plot displaying the separation between the two sample groups (AD = blue; controls = red). 
Explained variance (R2) was 97%, predictive ability (Q2) was 93%, and root-mean-square error of 
validation (RMSEV) was 15%. (C) The loadings plots which correspond to the scores in B. 
Indicated in blue (n = 24) and red (n = 17) are metabolites which significantly differ between 
groups (higher in AD and controls, respectively). These are further emphasized by the S-line-plot 
(D) and their relative variable importance to the model. (Reproduced from [94]). 
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Figure 6. Comparison of individualized metabolomic profiles and affected metabolic pathways in 
FAD mouse models. A, B and C (left panels): PLS-DA score plots showing distinct metabolomic 
profiles of PS1 (A), APP (B) and APP/PS1 (C) female mutant mice (Tg)) compared to non-
transgenic (NTG) littermates. A, B and C (central panels): Panels of specific biomarkers as a plot 
of variable importance in the projection (VIP) indicating the 15 most significant metabolites in 
discriminating between metabolomic profiles of NTG and Tg groups in the PLS-DA model. A, B 
and C (right panels): Metabolic pathways specifically affected in each FAD mouse model. 
(Reproduced from [111]). 
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Table 1. Metabolomic applications in AD research. 
Sample Groups of samples Metabolomic approach Analytical Platform Ref. 
Post-mortem CSF 23 samples from AD patients and healthy controls  Metabolic profiling of 2.4-2.9 NMR region NMR [74] 
Post-mortem human brain Subjects with no dementia (n=5), very mild dementia (n=3), mild dementia (n=4), moderate dementia (n=6) and severe dementia (n=4) Lipid profiling ESI-QqQ MS [75] 
CSF Demented patients (n=12), healthy subjects (n=17), multiple sclerosis patients (n=19) 
Metabolic profiling of 
oxidative metabolism NMR [76] 
Serum MCI (n=19) y control (n=26) subjects. Lipid profiling NMR [77] 
Post-mortem human brain AD patients (n=9) and control subjects (n=10). Metabolic profiling of 
cholesterol metabolism 
HPLC-Q/MS 
NMR [78] 
Post-mortem mice brain 8 brain regions from young mice TgCRND8 (n=5) and control young mice (n=4), and aged mice TgCRND8 (n=3) and control old mice (n=5). Metabolic fingerprinting NMR [87] 
Post-mortem human brain AD (n=8) and AML (n=11) patients. Metabolic fingerprinting NMR [88] 
Rat urine Control (n=4) and transgenic APP/tau rats at three life-time points: 4 (n=4), 10 (n=4) and 15 (n=3) months. Metabolic fingerprinting NMR [89] 
CSF Healthy subjects with typical AD biomarkers (Aβ y tau) (n=10) and without 
typical AD biomarkers (n=34). Metabolic fingerprinting NMR [90] 
Plasma AD patients (n=20), healthy subjects (n=20) Metabolic fingerprinting UHPLC-QqQ/MS [91] 
CSF AD patients (n=79) and control subjects (n=51). Metabolic fingerprinting GC-TOF MS LC-MS/MS [92] 
CSF  AD (n=23), MCI with progression to AD (n=9), MCI without progression to AD (n=22) and control (n=19) subjects. Validation set (n=12) Metabolic fingerprinting CE-TOF MS [93] 
Post-mortem human brain AD patients (n=15) and control subjects (n=15). Validation set (n=60). Metabolic fingerprinting UHPLC-Q/TOFMS [94] 
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CSF, Plasma, Urine AD patients (n=8), healthy subjects (n=8) Metabolic profiling of amino 
acids and dipeptides HPLC-MS
2
 [98] 
Post-mortem CSF AD patients (n=15) and control subjects (n=15). Metabolic fingerprinting HPLC-ECA [101] 
CSF 4 pool of samples from AD (n=27), MCI with progression to AD (n=13), MCI 
without progression to AD (n=26) and control (n=46) subjects. 
Metabolic profiling of amino 
acids MEKC-LIF [102] 
CSF AD (n=21), MCI with progression to AD (n=12), MCI without progression to AD (n=21) and control (n=21) subjects. Metabolic fingerprinting UHPLC-TOF MS [103] 
CSF AD patients (n=18), healthy subjects (n=18) Hydrophilic metabolites profiling nLC-Q/TOF MS [105] 
CSF AD (n=40), MCI (n=36) and control (n=38) subjects. Metabolic fingerprinting HPLC-ECA [108] 
CSF AD patients (n=40) and control subjects (n=38). Metabolic fingerprinting HPLC-ECA GC-TOF MS [109] 
Post-mortem mice brain Control (n=3) and transgenic (APP/PS1) (n=3) mice. Metabolic profiling of energetic 
metabolism GC-TOF MS [111] 
CSF and Plasma AD (n=15), MCI (n=10) and control (n=10) subjects. Metabolic fingerprinting UHPLC-TOF MS [123] 
Serum AD (n=37), MCI with progression to AD (n=52), MCI without progression to AD (n=91) and control (n=46) subjects. 
Lipid profiling 
Metabolic fingerprinting 
UHPLC-MS 
GC x GC-TOF MS [124] 
Plasma AD (n=16), MCI (12) and control (n=10) subjects. Metabolic profiling of bile 
acids UHPLC-MS/MS [131] 
Plasma AD (n=10), MCI (n=10) and control (n=10) subjects Phospholipid profiling HPLC-LTQ Orbitrap [132] 
Plasma AD patients (n=26) and control subjects (n=26). Lipid profiling QqQ-MS/MS [133] 
CSF and Plasma  Training set (CSF and plasma): AD patients (n=10) and control subjects (n=10). Validation set (Plasma): AD (n=41), MCI (n=26) and control (n=42) subjects. Steroid profiling 
HPLC-Q/MS 
LTQ Orbitrap [139] 
Post-mortem human brain 
Post-mortem mice brain 
AD patients (n=30) and control subjects (n=14). 
APPswedish mice (n=5) and control mice (n=8). Phospholipid profiling FIA
a
-MS/MS [150] 
aFIA: Flow Injection Analysis 
